

# Benefits of fitting non contact lens wearers with astigmatism with MyDay® 1-day toric contact lenses

<b>Submission date</b> 18/03/2025	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 26/03/2025	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 18/03/2025	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Some clinical evidence suggests that eye discomfort with soft toric contact lenses is different to that experienced by spherical soft contact lens wearers.

The aim of this study is to assess and compare eye comfort during contact lens wear with spherical and toric soft contact lenses in population of non contact lens wearers.

### Who can participate?

Adults aged 18 to 35 years with no previous contact lens wearing experience  
astigmatism (imperfection in the curvature of the eye)

### What does the study involve?

The participants will attend the clinic for two study visits and will complete a series of questionnaires while wearing the study contact lenses. At the first visit the participant will be fitted with the relevant study contact lenses MyDay spherical for the control group and MyDay toric for the test group.

The study contact lenses will be worn for one month under daily disposable wearing modality. At visit 2 comfort and the vision satisfaction will be assessed by the investigators.

### What are the possible benefits and risks of participating?

Participants have the opportunity to try contact lenses to correct their astigmatism. Any contact lens wear comes at the risk of corneal infection, but the incidence is very low.

### Where is the study run from?

Ocular Technology Group - International (OTG-i) (UK)

### When is the study starting and how long is it expected to run for?

March 2025 to October 2025

### Who is funding the study?

CooperVision International Limited (UK)

Who is the main contact?  
Deborah Moore, dmoore@otg.co.uk

## Contact information

### Type(s)

Scientific, Principal Investigator

### Contact name

Prof Michel Guillon

### Contact details

66 Buckingham Gate  
London  
United Kingdom  
SW1E 6AU  
+44 2072224224  
MGuillon@otg.co.uk

### Type(s)

Public

### Contact name

Miss Deborah Moore

### Contact details

66 Buckingham Gate  
London  
United Kingdom  
SW1E 6AU  
+44 2072224224  
dmoore@otg.co.uk

## Additional identifiers

### EudraCT/CTIS number

Nil known

### IRAS number

354030

### ClinicalTrials.gov number

Nil known

### Secondary identifying numbers

Nil known

## Study information

**Scientific Title**

Benefits of fitting neophyte astigmat with MyDay® 1-Day toric contact lenses

**Study objectives**

The primary hypothesis to be tested is that ocular comfort of neophytes astigmats fitted with the MyDay® 1-Day toric contact lenses is non-inferior to ocular comfort of neophytes non-astigmats or exhibiting very low astigmatism fitted with MyDay® 1-Day Asphere contact lenses. The secondary hypothesis to be tested is that the vision satisfaction of neophytes astigmats fitted with the MyDay® 1-Day toric contact lenses is non-inferior to vision satisfaction of neophytes non-astigmats or exhibiting very low astigmatism fitted with MyDay® 1-Day Asphere contact lenses.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

Approved 12/03/2025, North of Scotland Research Ethics Committee (Summerfield House, 2 Eday Road, Aberdeen, AB15 6RE, United Kingdom; +44 1224558458; gram.nosres@nhs.scot), ref: 25/NS/0025

**Study design**

Interventional open-label prospective investigator masked study following a parallel group study design

**Primary study design**

Interventional

**Secondary study design**

Non randomised study

**Study setting(s)**

Other

**Study type(s)**

Efficacy

**Participant information sheet**

Not available in web format, please use contact details to request a participant information sheet

**Health condition(s) or problem(s) studied**

Astigmatism

**Interventions**

The participants will attend the clinic for two study visits and will complete a series of questionnaires while wearing the study contact lenses. At the first visit the participant will be fitted with the relevant study contact lenses MyDay spherical for the control group and MyDay toric for the test group.

The study contact lenses will be worn for one month under daily disposable wearing modality. At visit 2 comfort and the vision satisfaction will be assessed by the investigators.

**Intervention Type**

Device

**Pharmaceutical study type(s)**

Not Applicable

**Phase**

Phase IV

**Drug/device/biological/vaccine name(s)**

MyDay® 1-Day Toric® & MyDay® 1-Day Asphere

**Primary outcome measure**

Ocular comfort on a 100-point visual analog scale during the one month study visit

**Secondary outcome measures**

Vision satisfaction on a 100-point visual analog scale during the one month study visit.

**Overall study start date**

04/01/2025

**Completion date**

31/10/2025

**Eligibility****Key inclusion criteria**

1. Age 18 to 35 years
2. No previous contact lens wearing experience
3. Spectacle refraction:  
Sphere: -6.00D to + 2.00D  
Astigmatism:  
Control group: 0.00D to -0.50D in each eye  
Test group: -0.75D to -2.00D in each eye
4. Best corrected visual acuity of at least 20/25 in each eye

**Participant type(s)**

Healthy volunteer

**Age group**

Adult

**Lower age limit**

18 Years

**Upper age limit**

35 Years

**Sex**

Both

**Target number of participants**

50

**Key exclusion criteria**

1. Acute and subacute inflammation or infection of the anterior chamber of the eye.
2. Any eye disease, injury or abnormality that affects the cornea, conjunctiva or eyelids that would contraindicate contact lens wear.
3. Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic.
4. Severe insufficiency of lacrimal secretion (dry eyes).
5. Any systemic disease that may affect the eye or may be exaggerated by wearing contact lenses (e.g. acne and eczema).
6. Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions.
7. Any active corneal infection (bacterial, fungal, protozoal or viral).
8. Newly prescribed (within the past 30 days) use of some systemic medications (such as antihistamines, decongestants, diuretics, muscle relaxants, tranquilizers, stimulants, anti-depressants, anti-psychotics, oral contraceptives) or new prescription eyedrops which is not rewetting/lubricating eyedrops for which contact lens wear could be contraindicated as determined by the investigator.
9. Monocular participants (only one eye with functional vision) or participants fit with only one contact lens.
10. Subjects with slit lamp findings greater than grade 1 (e.g. edema, infiltrates, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival, anterior segment inflammation) as per ISO 11980, any previous history or signs of a contact lens related corneal inflammatory event (past corneal ulcers), or any other ocular abnormality that may contraindicate contact lens wear at the enrolment visit.
11. History of corneal refractive surgery.
12. Enrolment of the family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals.

**Date of first enrolment**

30/03/2025

**Date of final enrolment**

31/10/2025

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Ocular Technology Group International**

66 Buckingham Gate

London

United Kingdom

SW1E 6AU

# Sponsor information

## Organisation

CooperVision International Limited

## Sponsor details

Delta Park, Concorde Way

Segensworth North

Fareham

England

United Kingdom

PO15 5RL

+44 (0)19252516682

PLazon@coopervision.com

## Sponsor type

Industry

## Website

<https://coopervision.com>

# Funder(s)

## Funder type

Industry

## Funder Name

CooperVision

## Alternative Name(s)

CooperVision, Inc., CooperVision Inc, CooperVision Inc., CooperVision, Inc

## Funding Body Type

Government organisation

## Funding Body Subtype

For-profit companies (industry)

## Location

United States of America

# Results and Publications

## Publication and dissemination plan

There are no plans at this stage for publication or dissemination.

## Intention to publish date

## Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

## IPD sharing plan summary

Not expected to be made available